To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

Inclusion Criteria: 1. The pathological diagnosis is non-squamous cell carcinoma and non-small cell lung cancer. The pre-treatment tumor stage is stage II-IIIA; 2. The gene detects EGFR mutations is positive; 3. The age is between 18-70 years; 4. ECOG 0-1; 5. Liver and kidney function and Bone marrow hematopoiesis is normal; 6. There are no serious systemic, respiratory, cardiovascular and other important systemic dysfunctions and severe malnutrition; 7. No other malignant diseases within 5 years; 8. Patients who have not received radiotherapy, systemic chemotherapy, or biological therapy; 9. Understand the whole process of the trial and voluntarily participate in and sign the informed consent form. Exclusion Criteria: 1. The tumor has invaded the surrounding tissue; 2. Preoperative evidence suggests that distant metastases of the lesion include contralateral mediastinal lymph node metastasis; 3. Arrhythmias require anti-arrhythmia therapy (β-blocker or digoxin Except), symptomatic coronary artery disease or myocardium. Ischemic or congestive heart failure exceeds NYHA class II; 4. severe hypertension with poor drug control; 5. moderate to severe proteinuria; 6. HIV fluHistory of infection or active chronic hepatitis B or C; 7. Malnutrition, decompensation of organ function; 8. History of chest radiotherapy; 9. Incomplete inflammation of eyes; 10. Patients with seizures that need to be treated; 11. Interstitial pneumonia; 12. Drug abuse and others that may interfere with patients' participation in the study or studyThe assessment of the results has an impact; 13. Allergies to the study drug are known or suspected to be allergic to or administered to any drug associated with this test; 14. Any instability. The condition of the patient may jeopardize patient safety and compliance; 15. Pregnancy or breastfeeding women and having fertility without adequate contraception.